Neurocrine Biosciences, Inc (NASDAQ:NBIX) announced that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the 26th Annual Roth Conference in Laguna. Neurocrine Biosciences, Inc. (NASDAQ:NBIX) shares after opening at $16.00 moved to $16.32 on last trade day and at the end of the day closed at $15.24. Company price to sales ratio in past twelve months was calculated as 395.98 and price to cash ratio as 7.88. Neurocrine Biosciences, Inc. (NASDAQ:NBIX) showed a negative weekly performance of -7.47%.
Actavis plc (NYSE:ACT) confirmed that the United States Court of Appeals for the Federal Circuit has reversed a lower court ruling that Actavis plc (NYSE:ACT)’ generic version of Shire’s Lialda® (mesalamine extended-release tablets) infringes United States Patent No. 6,773,720 (the ‘720 Patent). Actavis plc (NYSE:ACT) shares advanced 0.44% in last trading session and ended the day on $2023.77. Actavis plc (NYSE:ACT) return on equity ratio is recorded as -14.70% and its return on assets is -4.70%. Actavis plc (NYSE:ACT) yearly performance is 123.75%.
Horizon Pharma Inc (NASDAQ:HZNP) has been downgraded by TheStreet Ratings from hold to sell. Horizon Pharma Inc (NASDAQ:HZNP) shares moved down -1.79% in last trading session and was closed at $14.81, while trading in range of $14.77 – $15.50. Horizon Pharma Inc (NASDAQ:HZNP) year to date (YTD) performance is 94.36%.
The Board of Directors of Zoetis Inc. (NYSE:ZTS) declared a second quarter dividend payable to holders of the company’s common stock of $0.072 per share. Zoetis Inc (NYSE:ZTS) weekly performance is -0.85%. On last trading day company shares ended up $29.01. Zoetis Inc (NYSE:ZTS) distance from 50-day simple moving average (SMA50) is -4.33%. Analysts mean target price for the company is $34.75.